Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.59 |
| ▸ | DRD4 | P21917 | 7/20 | 0.59 |
| ▸ | DRD3 | P35462 | 7/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044318 | 0.93 | DRD2 (0.57) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL11428669 | 0.91 | DRD2 (0.55) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL8778598 | 0.91 | DRD2 (0.55) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL1045912 | 0.91 | DRD2 (0.55) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL1047647 | 0.88 | DRD2 (0.55) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL5929468 | 0.85 | DRD2 (0.68) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL3805304 | 0.85 | DRD2 (0.68) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL8778513 | 0.84 | LTA4H (0.57) | SMN1; SMN2 | |
| SCHEMBL11510407 | 0.84 | DRD2 (0.52) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL9011831 | 0.83 | DRD2 (0.65) | DRD2DRD4DRD3L3MBTL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101230049-A | Hydroxamic acid histone deacetylase inhibitor as well as preparation method and use thereof | UNIV CHINA PHARMA (CN) | 2008-07-30 | — | — | CN | claimed |
| EP-3388454-A1 | METHOD OF PRODUCING (METH)ACRYLOYL-TERMINATED POLYISOBUTYLENE POLYMER | Kaneka Corporation (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| CN-102895230-A | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMA CO LTD | 2013-01-30 | — | — | CN | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| CN-1289739-A | Manufacture of formed refractory products | JAPAN CASTING TECHNOLOGY CONSU (JP) | 2001-04-04 | — | — | CN | disclosed |
| CN-1289655-A | Method for making formed refractory casting mould with core installed | JAPAN CASTING TECHNOLOGY CONSU (JP) | 2001-04-04 | — | — | CN | disclosed |
| EP-1004304-A1 | COMPOSITION CONTAINING ASCORBIC ACID | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-05-31 | — | — | EP | disclosed |
| EP-0661246-B1 | Process for preparing refractory molded articles and binders therefor | CADIC CORP (JP) | 1999-09-01 | — | — | EP | disclosed |
| US-5611848-A | Process for preparing refractory molded articles and binders therefor | CADIC CORPORATION (JP) | 1997-03-18 | — | — | US | disclosed |
| US-5569320-A | ORNAMENTS, MOLDS OR A CORE | CADIC CORPORATION (JP) | 1996-10-29 | — | — | US | disclosed |
| EP-0661246-A1 | Process for preparing refractory molded articles and binders therefor | CADIC CORPORATION (JP) | 1995-07-05 | — | — | EP | disclosed |
| US-4918074-A | CALCIUM ANTAGONISTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-04-17 | — | — | US | disclosed |
| EP-0217142-A2 | A polyazaheterocyclic compound | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1987-04-08 | — | — | EP | disclosed |
| EP-0193813-A1 | Pyridine derivatives and fungicides containing them | BASF Aktiengesellschaft (DE) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DRD2 2614/4885DRD4 888/4885DRD3 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.